This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NovaBay Pharmaceuticals Reports First Quarter Financial Results And Clinical And Business Update

Clinical Results From Three Aganocide ® Trials Expected in Second Half of 2013

EMERYVILLE, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the large global, topical anti-infective market, today reported first quarter financial results and provided a clinical update for the remainder of 2013.

Dr. Ron Najafi, Chairman and CEO of NovaBay Pharmaceuticals, commented: "All three of our Aganocide programs - in urology, dermatology, and ophthalmology - are now in Phase 2 clinical trials, and we are expecting results from each of these trials in 2013. We continue to strengthen our portfolio of drugs and medical devices that fulfill our mission of going 'beyond antibiotics.' By providing a treatment alternative to the several currently available resistance-producing topical antibiotics, we believe our technology has the potential to slow down the steady advance of antibiotic resistance."

First Quarter 2013 Results

Cash, cash equivalents, and short-term investments totaled $13.2 million on March 31, 2013, compared with $16.9 million on December 31, 2012, a decrease of approximately $3.7 million. The decrease in cash was primarily attributable to an increase in NovaBay's research and development expenses related to continued expansion of enrollment in its multiple clinical trials, with results expected before the end of 2013, as well as general and administrative expenses.

NovaBay's license and collaboration revenue for the first quarter 2013 was $0.9 million, compared to $1.3 million for the three months ended March 31, 2012. This decrease was related to lower reimbursable costs for the support of the impetigo trial as the trial progresses. NovaBay did not recognize any other significant revenues for the three months ended March 31, 2013.

Research and development expenses for the three months ended March 31, 2013, were $2.9 million, compared to $2.3 million for the same period in 2012. The increase is related to the clinical trial activities and patient enrollment as NovaBay continues to conduct its BAYNovation TM ophthalmology trial for viral conjunctivitis and its urology trial for UCBE and scales up its production of auriclosene in anticipation of the Phase 3 impetigo trial to be conducted by Galderma. Galderma is expected to reimburse NovaBay for a portion of the production expenses in the future.

General and administrative expenses for the three months ended March 31, 2013, remained relatively flat at $1.5 million compared to the three months ended March 31, 2012. NovaBay expects general and administrative expenses to continue to remain relatively flat for the remainder of 2013 as compared to 2012.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs